Janssen

TREMFYA

Manufacturer:

Janssen

Tremfya HCPCS:

J1628

HCPCS Code Descriptor:

Injection, guselkumab, 1 mg

Category:

J Code

Tremfya NDCs:

57894-0640-01, 57894-0640-11

Primary Type:

Immunology:Anti-TNF

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Tremfya:

TREMFYA is an Immunology:Anti-TNF drug manufactured by Janssen and administered via the Subcutaneous route of administration. The J Code: J1628 is aligned to the drug TREMFYA.

Tremfya is a monoclonal antibody that is used to treat certain skin and joint conditions. It works by blocking a certain protein which causes immune responses and is administered via subcutaneous injection. Tremfya is a branded drug manufactured by Janssen Biotech. Prior to receiving its J Code: J1628 in January 2019, Tremfya was aligned to the C Code: C9029.Patient assistance programs for Tremfya can be found through the Johnson & Johnson Patient Assistance Program.

ACCESS PRICING AND MORE BY REGISTERING

J1628 Added Date:

January 1, 2019

J1628 Effective Date:

January 1, 2019

J1628 Termination Date:

HCPCS Active

Tremfya billing and coding information can be found through Janssen at the link below:
Tremfya patient assistance information can be found through The Johnson and Johnson Patient Assistance Foundation at the URL: https://www.jjpaf.org/apply/
TREMFYA prescribing information can be found at the link below:
Information regarding TREMFYA’s side effects can be found at MedlinePlus